Further investigations revealed the ability of LXA4 to rescue macrophage-induced desensitization to insulin-stimulated signaling and glucose uptake in cultured adipocytes, thus suggesting that LXA4 may represent a potentially useful and novel therapeutic strategy to subvert adipose inflammation and insulin resistance, key components of T2D (Borgeson et al., 2012). The gene discussed is INS; the disease is type 2 diabetes mellitus.